Current Clinical Microbiology Reports最新文献_第8页

Cardiovascular Injury Due to SARS-CoV-2. SARS-CoV-2 导致的心血管损伤。

IF 3.1

Current Clinical Microbiology Reports Pub Date : 2021-01-01 Epub Date: 2021-03-05 DOI: 10.1007/s40588-021-00160-0

Christina L Bugert, Victoria Kwiat, Isela C Valera, Joachim J Bugert, Michelle S Parvatiyar

{"title":"Cardiovascular Injury Due to SARS-CoV-2.","authors":"Christina L Bugert, Victoria Kwiat, Isela C Valera, Joachim J Bugert, Michelle S Parvatiyar","doi":"10.1007/s40588-021-00160-0","DOIUrl":"10.1007/s40588-021-00160-0","url":null,"abstract":"Purpose of review: The world is currently facing the largest global health crisis since the early 1900s due to a novel coronavirus. While SARS-CoV-2 infection causes predictable symptoms in COVID-19 patients, including upper respiratory distress and fever, the heterogeneity of manifestations is surprising. This review focuses on direct and indirect causes of myocardial injury in COVID-19 patients and highlights current knowledge, treatment strategies, and outstanding questions in the field.Recent findings: Data are emerging that highlight the extent of cardiovascular involvement in COVID-19 patients, including evidence that SARS-CoV-2 causes myocarditis and increases cardiac risk. The incidence of cardiac injury is much greater in patients with severe disease presentation and those in intensive care.Summary: During the past year, COVID-19 patient mortality rates have improved due to tailored pharmacological treatments and patient management strategies that address the unique presentation of symptoms, which will hopefully also reduce the incidence of cardiac injury.","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25477102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Review of Coccidioides Research, Outstanding Questions in the Field, and Contributions by Women Scientists. 球虫学研究综述、领域内的突出问题及女科学家的贡献。

IF 5.2

Current Clinical Microbiology Reports Pub Date : 2021-01-01 Epub Date: 2021-08-02 DOI: 10.1007/s40588-021-00173-9

Morgan E Gorris, Marley C Caballero Van Dyke, Adrienne Carey, Paris S Hamm, Heather L Mead, Jessie K Uehling

{"title":"A Review of Coccidioides Research, Outstanding Questions in the Field, and Contributions by Women Scientists.","authors":"Morgan E Gorris, Marley C Caballero Van Dyke, Adrienne Carey, Paris S Hamm, Heather L Mead, Jessie K Uehling","doi":"10.1007/s40588-021-00173-9","DOIUrl":"https://doi.org/10.1007/s40588-021-00173-9","url":null,"abstract":"Purpose of review: Coccidioidomycosis is an infectious disease that gained clinical significance in the early 20th century. Many of the foundational contributions to coccidioidomycosis research, including the discovery of the fungal disease agent, Coccidioides spp., were made by women. We review recent progress in Coccidioides research and big questions remaining in the field, while highlighting some of the contributions from women.Recent findings: New molecular-based techniques provide a promising method for detecting Coccidioides, which can help determine the dominate reservoir host and ideal environmental conditions for growth. Genetic and genomic analyses have allowed an understanding of population structure, species level diversity, and evolutionary histories. We present a current, comprehensive genome list, where women contributed many of these entries. Several efforts to develop a coccidioidomycosis vaccine are underway.Summary: Women continue to pioneer research on Coccidioides, including the relationships between the fungi and the environment, genetics, and clinical observations. Significant questions remain in the field of Coccidioides, including the main host reservoir, the relationships between genotypic and phenotypic variation, and the underlying cause for chronic clinical coccidioidomycosis cases.","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":null,"pages":null},"PeriodicalIF":5.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327307/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39300960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Cryptosporidium: Host-Parasite Interactions and Pathogenesis. 隐孢子虫:宿主-寄生虫相互作用及其发病机制。

IF 5.2

Current Clinical Microbiology Reports Pub Date : 2021-01-01 Epub Date: 2021-02-08 DOI: 10.1007/s40588-021-00159-7

Derek J Pinto, Sumiti Vinayak

{"title":"Cryptosporidium: Host-Parasite Interactions and Pathogenesis.","authors":"Derek J Pinto, Sumiti Vinayak","doi":"10.1007/s40588-021-00159-7","DOIUrl":"https://doi.org/10.1007/s40588-021-00159-7","url":null,"abstract":"Purpose of review: Cryptosporidium spp. (C. hominis and C. parvum) are a major cause of diarrhea-associated morbidity and mortality in young children globally. While C. hominis only infects humans, C. parvum is a zoonotic parasite that can be transmitted from infected animals to humans. There are no treatment or control measures to fully treat cryptosporidiosis or prevent the infection in humans and animals. Our knowledge on the molecular mechanisms of Cryptosporidium-host interactions and the underlying factors that govern infectivity and disease pathogenesis is very limited.Recent findings: Recent development of genetics and new animal models of infection, along with progress in cell culture platforms to complete the parasite lifecycle in vitro, is greatly advancing the Cryptosporidium field.Summary: In this review, we will discuss our current knowledge of host-parasite interactions and how genetic manipulation of Cryptosporidium and promising infection models are opening the doors towards an improved understanding of parasite biology and disease pathogenesis.","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":null,"pages":null},"PeriodicalIF":5.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40588-021-00159-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25371897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 23

COVID-19 Pandemic and the Convalescent Plasma Therapy: Possible Benefits and Risks. COVID-19大流行与恢复期血浆治疗:可能的益处和风险。

IF 5.2

Current Clinical Microbiology Reports Pub Date : 2021-01-01 Epub Date: 2021-07-03 DOI: 10.1007/s40588-021-00174-8

Rashed Noor, Nishat Tasnim, Chandrika Saha

{"title":"COVID-19 Pandemic and the Convalescent Plasma Therapy: Possible Benefits and Risks.","authors":"Rashed Noor, Nishat Tasnim, Chandrika Saha","doi":"10.1007/s40588-021-00174-8","DOIUrl":"https://doi.org/10.1007/s40588-021-00174-8","url":null,"abstract":"Purpose of review: COVID-19 pandemic has been the major threat to the global public health for a year (last of 2019-till date); and unfortunately, there is still as no specific antiviral agent which can be effectively used against this disease curation. Present review focused on the application of the convalescent plasma (CP) therapy as a quick remediation of the disease severity.Recent findings: While several drugs have been repurposed based on a number of completed clinical trials together with a huge ongoing effort to develop appropriate vaccine against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the therapeutic approach of the CP therapy appears to be one of the effective methods to rescue the severely affected COVID-19 patients. Such a therapy based on passive immunity evolved from the SARS-CoV-2-infected patients who have fully recovered from COVID-19; and hence these individuals are quite likely to possess high titers of the SARS-CoV-2-neutralizing immunoglobulins (antibodies). However, there are some risks such therapy, and its effectivity also appeared doubtful in some cases. Thus, the current review discussed the issues raised by the administration of such plasma into the SARS-CoV-2-infected individuals.Summary: Application of CP therapy has been conducted since long time; and for the mitigation of COVID-19 severity, such pharmaceutical strategy is also being employed in spite of several risks which actually can be monitored as well as optimized in order to combat the SARS-CoV-2 infection.","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":null,"pages":null},"PeriodicalIF":5.2,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40588-021-00174-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39174651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Host Mitochondrial Requirements of Cytomegalovirus Replication. 巨细胞病毒复制对宿主线粒体的要求。

IF 5.2

Current Clinical Microbiology Reports Pub Date : 2020-12-01 Epub Date: 2020-09-30 DOI: 10.1007/s40588-020-00153-5

Chandler H Monk, Kevin J Zwezdaryk

引用次数: 6

Fungal Infections Associated With the Use of Novel Immunotherapeutic Agents. 真菌感染与新型免疫治疗剂的使用有关。

IF 5.2

Current Clinical Microbiology Reports Pub Date : 2020-12-01 Epub Date: 2020-09-26 DOI: 10.1007/s40588-020-00154-4

Marilia Bernardes, Tobias M Hohl

{"title":"Fungal Infections Associated With the Use of Novel Immunotherapeutic Agents.","authors":"Marilia Bernardes, Tobias M Hohl","doi":"10.1007/s40588-020-00154-4","DOIUrl":"https://doi.org/10.1007/s40588-020-00154-4","url":null,"abstract":"Purpose of the review: Recent concerns have emerged regarding the potential of immunotherapy to cause infection. In this review, we summarize the current literature on invasive fungal infections that occur during treatment with immune checkpoint inhibitors and chimeric antigen receptor T cell therapy.Recent findings: Fungal infections are uncommon with the use of checkpoint inhibitors. Most cases are caused by invasive aspergillosis and pneumocystis pneumonia and occur in patients requiring high dose corticosteroids for the management of immune-related adverse events. Conversely, fungal infections are commonly reported during therapy with CAR T cells. Most cases are caused by invasive aspergillosis and candidiasis and are likely the result of prolonged neutropenia following the conditioning regimen or immunosuppressant use for the management of cytokine release syndrome and neurotoxicity.Summary: Treatment-related toxicities that require prolonged immunosuppressive agents appear to play a key role in the development of fungal infections during immunotherapy. Ongoing surveillance is needed to fully address the risks of fungal infections with these novel agents.","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":null,"pages":null},"PeriodicalIF":5.2,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40588-020-00154-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39266303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12

Role of Non-coding RNAs in Fungal Pathogenesis and Antifungal Drug Responses 非编码RNA在真菌发病机制和抗真菌药物反应中的作用

IF 5.2

Current Clinical Microbiology Reports Pub Date : 2020-10-02 DOI: 10.1007/s40588-020-00151-7

S. Dhingra

引用次数: 5

Candida auris infection and biofilm formation: going beyond the surface. 耳念珠菌感染与生物膜形成:超越表面。

IF 5.2

Current Clinical Microbiology Reports Pub Date : 2020-09-01 Epub Date: 2020-07-17 DOI: 10.1007/s40588-020-00143-7

Mark V Horton, Jeniel E Nett

引用次数: 50

Mycobacterium avium: an Emerging Pathogen for Dog Breeds with Hereditary Immunodeficiencies. 鸟分枝杆菌:一种遗传性免疫缺陷犬种的新兴病原体。

IF 5.2

Current Clinical Microbiology Reports Pub Date : 2020-09-01 Epub Date: 2020-08-18 DOI: 10.1007/s40588-020-00145-5

Giovanni Ghielmetti, Urs Giger

{"title":"Mycobacterium avium: an Emerging Pathogen for Dog Breeds with Hereditary Immunodeficiencies.","authors":"Giovanni Ghielmetti, Urs Giger","doi":"10.1007/s40588-020-00145-5","DOIUrl":"https://doi.org/10.1007/s40588-020-00145-5","url":null,"abstract":"Purpose of review: Among the nontuberculous mycobacteria (NTM), Mycobacterium avium complex (MAC) is the leading cause of pulmonary disease in humans. Innate and acquired immunodeficiencies have been associated with an increased host susceptibility to NTM infections. The underlying mechanisms predisposing humans and dogs to MAC infections is being elucidated.Recent findings: Although MAC infection is infrequently diagnosed in dogs, a strong breed predisposition particularly for Miniature Schnauzer and Basset Hound dogs is evident. A recessively inherited defect of the adaptor protein CARD9 has recently been documented to be responsible for the increased susceptibility to MAC in the Miniature Schnauzer breed.Summary: Given the zoonotic potential of a MAC infected dog particularly to immunocompromised human patients, diseased dogs pose a public health risk. While not a reportable disease, treatment of systemic mycobacteriosis is generally not effective and discouraged in dogs. The collaborative efforts by microbiologists, veterinary clinicians, dog breeders, primary care physicians, and infectious disease specialists applying the One Health approach is therefore crucial for the best management and prevention of MAC infection.","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":null,"pages":null},"PeriodicalIF":5.2,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40588-020-00145-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25591205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

Persistence in Livestock Mycoplasmas—a Key Role in Infection and Pathogenesis 家畜支原体的持久性:感染和发病的关键作用

IF 5.2

Current Clinical Microbiology Reports Pub Date : 2020-07-24 DOI: 10.1007/s40588-020-00149-1

K. Hoelzle, Julia Ade, L. Hoelzle

引用次数: 11